08.25.15
Bekki Brown and Tom Zoda, Ph.D., have been appointed to executive vice president, Clinical Development, General Medicine at INC Research, and executive vice president, Clinical Development, Central Nervous System (CNS), respectively, responsible for providing executive leadership for two of the company's therapeutic business units.
"Having built our organization around our therapeutic depth, we are delighted to appoint Bekki and Tom to further expand our therapeutic offerings in these important and fast-growing market segments," said Michael Gibertini, PhD, President, Clinical Development. "INC is focused on providing specialized teams and experts in particular disciplines that fully understand each therapy area and how to best address customers' needs. By structuring teams in this way, we are able to deliver unique insights that provide a clear advantage in accelerating new therapies to market for the benefit of patients in need."
Ms. Brown joined the company in 2001, and provides global leadership for the company's General Medicine business unit, which specializes in clinical trials in areas ranging from infectious disease, respiratory disease, immunology and inflammation, gastrointestinal diseases, urology and women's health. Since 2010, she has led operations and guided the group to its highest-ever level of performance.
Dr. Zoda has worked in the pharmaceutical and CRO industry for more than 20 years, and has extensive experience designing, managing and overseeing clinical trials for the development of CNS therapeutics. He takes over the CNS unit from Dr. Gibertini, who now focuses on driving innovation and leveraging efficiencies across all of INC's therapeutic
business units. Since joining the company in 2009, he has directed large multi-center global trials focused on psychiatric and neurologic indications in areas such as schizophrenia, Alzheimer's Disease, depression, anxiety, multiple sclerosis and epilepsy.
"Having built our organization around our therapeutic depth, we are delighted to appoint Bekki and Tom to further expand our therapeutic offerings in these important and fast-growing market segments," said Michael Gibertini, PhD, President, Clinical Development. "INC is focused on providing specialized teams and experts in particular disciplines that fully understand each therapy area and how to best address customers' needs. By structuring teams in this way, we are able to deliver unique insights that provide a clear advantage in accelerating new therapies to market for the benefit of patients in need."
Ms. Brown joined the company in 2001, and provides global leadership for the company's General Medicine business unit, which specializes in clinical trials in areas ranging from infectious disease, respiratory disease, immunology and inflammation, gastrointestinal diseases, urology and women's health. Since 2010, she has led operations and guided the group to its highest-ever level of performance.
Dr. Zoda has worked in the pharmaceutical and CRO industry for more than 20 years, and has extensive experience designing, managing and overseeing clinical trials for the development of CNS therapeutics. He takes over the CNS unit from Dr. Gibertini, who now focuses on driving innovation and leveraging efficiencies across all of INC's therapeutic
business units. Since joining the company in 2009, he has directed large multi-center global trials focused on psychiatric and neurologic indications in areas such as schizophrenia, Alzheimer's Disease, depression, anxiety, multiple sclerosis and epilepsy.
